Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra and Tocilizumab with Nivolumab and Ipilimumab in Older Melanoma Patients
NCT07838974Phase 1Not yet recruiting
- Sponsor
- University of Southern California
- Start
- Nov 2026
- Primary completion
- Nov 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anakinra and tocilizumab in melanoma, sponsored by University of Southern California. Primary endpoint: Tolerated dose of the combination of anakinra and tocilizumab at 12 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
anakinratocilizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07838974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07838974.